Multi-omic analysis of SDHB-deficient pheochromocytomas and paragangliomas identifies metastasis and treatment-related molecular profiles
Aidan Flynn,Andrew D Pattison,Shiva Balachander,Emma Boehm,Blake Bowen,Trisha Dwight,Fernando Rosello,Oliver Hofmann,Luciano Martelotto,Maia Zethoven,Lawrence S Kirschner,Tobias Else,Lauren Fishbein,Anthony J Gill,Arthur S Tischler,Thomas Giordano,Tamara Prodanov,Jane R Noble,Roger R Reddel,Alison H Trainer,Hans Kumar Ghayee,Isabelle Bourdeau,Marianne Elston,Diana Ishak,Joanne Ngeow Yuen Yie,Rodney J Hicks,Joakim Crona,Tobias Åkerström,Peter Stålberg,Patricia Dahia,Sean Grimmond,Roderick Clifton-Bligh,Karel Pacak,Richard W Tothill
DOI: https://doi.org/10.21203/rs.3.rs-4410500/v1
2024-06-25
Abstract:Hereditary SDHB-mutant pheochromocytomas (PC) and paragangliomas (PG) are rare tumours with a high propensity to metastasize although their clinical behaviour is unpredictable. To characterize the genomic landscape of these tumours and identify metastasis biomarkers, we performed multi-omic analysis on 94 tumours from 79 patients using seven molecular methods. Sympathetic (chromaffin cell) and parasympathetic (non-chromaffin cell) PCPG had distinct molecular profiles reflecting their cell-of-origin and biochemical profile. TERT and ATRX-alterations were associated with metastatic PCPG and these tumours had an increased mutation load, and distinct transcriptional and telomeric features. Most PCPG had quiet genomes with some rare co-operative driver events observed, including EPAS1/HIF-2α mutations. Two mechanisms of acquired resistance to DNA alkylating chemotherapies were also detected - MGMT overexpression and mismatch repair-deficiency causing hypermutation. Our comprehensive multi-omic analysis of SDHB-mutant PCPG therefore identified features of metastatic disease and treatment response, expanding our understanding of these rare neuroendocrine tumours.